Abstract 87P
Background
Additional prognostic factors like Quality of Life (QoL) may benefit further stratification of risk for an individualized treatment allocation. Our study aimed to assess the association between preoperative QoL and long-term survival in patients undergoing surgical resection for pathological stage I non-small cell lung cancer (NSCLC).
Methods
A retrospective analysis was conducted on 388 consecutive patients who completed the QoL assessment through the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and lung cancer specific module (LC13), prior to anatomical lung resection for early-stage NSCLC (2014-2018). Median follow-up was 1685 days. Survival distribution was estimated by the Kaplan-Meier method. Cox proportional hazard regression and competing risk regression analyses were used to assess the independent association of preoperative patient-reported outcomes with overall and cancer-specific survival.
Results
Higher score in patient-reported Physical Functioning was significantly associated with longer overall survival. Other factors significantly associated with poorer overall survival remained older age (p=0.005), low BMI (p=0.007), male sex (p<0.001) and nodal involvement (p=0.007). A 70 year old male patient with a BMI of 27 and a pT1N0 stage would have an estimated 5-year overall survival of 65%, 50% and 35% in case of a baseline Physical Functioning of 80, 50 and 30, respectively. Even more interestingly, the same theoretical patient with positive nodal status would have 50% 5-year survival in case of a good baseline functional status PF=80. Competing regression analysis found that worse baseline lung cancer-specific dyspnoea was significantly associated with a poorer cancer-specific survival (p=0.03) along with low Body Mass Index (p=0.01), high Performance Status (p=0.03) and lymph node involvement (p=0.01).
Conclusions
A better patient-reported Physical Function score was associated with longer overall survival after curative resection for cancer. Our study highlights the significance of routinely collecting QoL data in clinical practice to aid preoperative decision making in early-stage NSCLC patients.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
G. Velikova: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Invited Speaker: Seattle genetics; Financial Interests, Personal, Invited Speaker: Snafu Genzyme. A. Brunelli: Financial Interests, Personal, Invited Speaker: BD; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Ethicon; Financial Interests, Personal, Invited Speaker: Medtronic. All other authors have declared no conflicts of interest.